Moxifloxacin ophthalmic solution - Alcon

Drug Profile

Moxifloxacin ophthalmic solution - Alcon

Alternative Names: AL-15469A; BAY-12-8039; BAY-X-8843; Kanavig; Moxafloxacin hydrochloride; Moxeza; Moxifloxacin hydrochloride ophthalmic solution - Alcon; Moxifloxacin hydrochloride otic solution - Alcon; Moxivig; Vegamox; Vigamox; Vigamoxi

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Bayer
  • Developer Alcon
  • Class Antibacterials; Azabicyclo compounds; Cyclopropanes; Fluoroquinolones; Piperidines; Pyrrolidines; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Infectious conjunctivitis; Postoperative infections
  • Discontinued Otitis externa

Most Recent Events

  • 01 Apr 2014 Alcon completes a phase III trial in bacterial Conjunctivitis in USA (NCT01573910)
  • 03 May 2012 Alcon initiates enrolment in a phase III trial in bacterial Conjunctivitis in USA (NCT01573910)
  • 09 Apr 2012 Alcon plans a phase III trial for Conjunctivitis in USA (NCT01573910)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top